 JENA, Germany, May 17, 2022 GLOBE NEWSWIRE -- InflaRx N.V. Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference. 